CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
CONMED CorporationNYSE: CNMD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $4.17M fell 77.1% year over year, behind the -10.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 77.9% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Depreciation & amortization amounted to 5.4% of revenue in FY2025, up 1.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -77.1% toward the trailing-twelve-month pace of -10.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 74.28M USD
- Year-over-year change
- +44.8%
- 4-year CAGR
- +1.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.28M | +44.8% |
| FY2024 | 2024-12-31 | 51.31M | -0.2% |
| FY2023 | 2023-12-31 | 51.4M | -26.1% |
| FY2022 | 2022-12-31 | 69.52M | -1.7% |
| FY2021 | 2021-12-31 | 70.74M | — |
Depreciation & Amortization vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 depreciation & amortization of $60.2M is the 3rd largest of the 11 companies compared; the peer median is $10.28M.
- Its year-over-year change of -10.3% is the 10th highest of 11, against a peer median of +0.9%.
- Depreciation & amortization amounts to 4.4% of revenue for CNMD, versus a peer median of 6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $416.38M | +10.6% | +2.8% | 14.6% | |
| LTM Aug 2026 | $117.65M | -5.8% | +8.7% | 13.3% | |
| LTM Mar 2026 | $60.2M | -10.3% | +2.2% | 4.4% | |
| LTM Sep 2026 | $56.52M | -7.7% | -12.9% | 9.1% | |
| LTM Jun 2026 | $19.66M | +9.0% | +17.2% | 3.1% | |
| LTM Sep 2026 | $10.57M | +4.6% | +34.1% | 4.0% | |
| LTM Mar 2026 | $9.99M | -2.7% | +10.7% | 15.1% | |
| LTM Jan 2026 | $8.22M | -14.7% | — | 9.8% | |
| LTM Mar 2026 | $6.43M | +26.3% | +11.3% | 1.0% | |
| LTM Mar 2026 | $1.19M | +110.8% | +123.3% | 2.5% | |
| LTM Mar 2026 | $696K | -5.6% | +0.7% | 0.2% | |
| Peer median (excluding CNMD) | $10.28M | +0.9% | +10.7% | 6.5% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Depreciation & Amortization | 70.74M | 69.52M | 51.4M | 51.31M | 74.28M |
| Deferred Income Tax | 3.01M | (6.04M) | 700K | 12.2M | 3.52M |
| Stock-Based Compensation | 16.34M | 21.73M | 24.26M | 25.56M | 28.32M |
| Change in Working Capital | (55.7M) | (90.7M) | (39.58M) | (39.72M) | (11.45M) |
| Accounts Receivables | (9.16M) | (5.2M) | (47.07M) | (1.62M) | (2.36M) |
| Inventory | (37.81M) | (78.56M) | 14.07M | (31.63M) | (6.73M) |
| Accounts Payables | 4.89M | 13.3M | 14.85M | 14.71M | (9.75M) |
| Other Working Capital | (13.62M) | (20.23M) | (21.43M) | (21.19M) | 7.39M |
| Other Non-Cash Items | 14.84M | 119.44M | 24.11M | (14.8M) | 28.96M |
| Operating Cash Flow | 111.77M | 33.37M | 125.35M | 166.97M | 170.69M |
| Capital Expenditures | (14.87M) | (21.79M) | (19.03M) | (13.08M) | (19.81M) |
| Acquisitions (Net) | 0 | (227.74M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | (1.15M) |
| Investing Cash Flow | (14.87M) | (249.53M) | (20.03M) | (13.08M) | (20.96M) |
| Debt Repayment | (81.24M) | 362.02M | (88M) | (72M) | (74.59M) |
| Common Stock Issued | 0 | 72M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (72M) | 0 | 0 | 0 |
| Dividends Paid | (23.26M) | (23.96M) | (24.5M) | (24.65M) | (24.75M) |
| Other Financing Activities | 2.95M | (113.06M) | 2.07M | (54.35M) | (36.49M) |
| Financing Cash Flow | (101.55M) | 225M | (110.43M) | (151M) | (135.82M) |
| Effect of Forex Changes | (1.87M) | (741K) | 470K | (2.72M) | 2.45M |
| Net Change in Cash | (6.51M) | 8.1M | (4.65M) | 163K | 16.36M |
| Free Cash Flow | 96.9M | 11.58M | 106.32M | 153.88M | 150.88M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.